PTX3 and cancer: Their results underline the utility of PTX-3 as a discriminating factor of benign prostatic hyperplasia from cancer, at the cut-off value of 3.25 ng/mL (88.5% specificity and 89.3% sensitivity) and also as potential quantifying factor for prostatic cancer risk development [34].